Literature DB >> 18474179

Treatment strategies for obesity-related hypertension.

Efrain Reisin.   

Abstract

Entities:  

Year:  2008        PMID： 18474179     DOI： 10.1007/s11906-008-0024-z

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  9 in total

1.  Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.

Authors:  F G McMahon; S P Weinstein; E Rowe; K R Ernst; F Johnson; K Fujioka
Journal:  J Hum Hypertens       Date:  2002-01       Impact factor: 3.012

2.  Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.

Authors:  J J Sramek; M T Leibowitz; S P Weinstein; E D Rowe; C M Mendel; B Levy; F G McMahon; W S Mullican; P D Toth; N R Cutler
Journal:  J Hum Hypertens       Date:  2002-01       Impact factor: 3.012

3.  Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension.

Authors:  W B White; W J Elliott; M F Johnson; H R Black
Journal:  J Hum Hypertens       Date:  2001-02       Impact factor: 3.012

4.  Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group.

Authors:  E Reisin; M R Weir; B Falkner; H G Hutchinson; D A Anzalone; M L Tuck
Journal:  Hypertension       Date:  1997-07       Impact factor: 10.190

5.  Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.

Authors:  Jürgen Scholze; Elmar Grimm; Dana Herrmann; Thomas Unger; Ulrich Kintscher
Journal:  Circulation       Date:  2007-04-02       Impact factor: 29.690

6.  Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.

Authors:  Jens Jordan; Stefan Engeli; Sam W Boye; Stephanie Le Breton; Deborah L Keefe
Journal:  Hypertension       Date:  2007-03-12       Impact factor: 10.190

7.  Prevalence and trends in obesity among US adults, 1999-2000.

Authors:  Katherine M Flegal; Margaret D Carroll; Cynthia L Ogden; Clifford L Johnson
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

8.  The treatment of obese hypertensive black women: a comparative study of chlorthalidone versus clonidine.

Authors:  E Reisin; S G Weed
Journal:  J Hypertens       Date:  1992-05       Impact factor: 4.844

Review 9.  Renal and cardiovascular considerations for the nonpharmacological and pharmacological therapies of obesity-hypertension.

Authors:  R Zhang; V Thakur; S Morse; E Reisin
Journal:  J Hum Hypertens       Date:  2002-12       Impact factor: 3.012
  9 in total
  1 in total

1.  Chinese herbal medicine for the treatment of obesity-related hypertension.

Authors:  Jie Wang; Bo Feng; Xingjiang Xiong
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-18       Impact factor: 2.629
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.